Cargando…
A Dose-Finding Trial for Hyperthermic Intraperitoneal Cisplatin in Gynecological Cancer Patients Receiving Hyperthermic Intraperitoneal Chemotherapy
Background: To identify the maximum tolerated dose (MTD) of hyperthermic intraperitoneal cisplatin at 43°C among gynecological cancer patients. Methods: In this Phase I dose-finding trial, Bayesian optimal interval (BOIN) design was used. We sought to explore the MTD with a target dose-limiting toxi...
Autores principales: | Chan, Chui-ying, Li, Hui, Wu, Miao-fang, Liu, Chang-hao, Lu, Huai-wu, Lin, Zhong-qiu, Li, Jing |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7991782/ https://www.ncbi.nlm.nih.gov/pubmed/33777754 http://dx.doi.org/10.3389/fonc.2021.616264 |
Ejemplares similares
-
Calculating the dose of cisplatin that is actually utilized in hyperthermic intraperitoneal chemotherapy among ovarian cancer patients
por: Wang, Wu-yun, et al.
Publicado: (2021) -
Tumor Mutational Burden Associated With Response to Hyperthermic Intraperitoneal Chemotherapy
por: Zeng, Lisi, et al.
Publicado: (2022) -
Temperature management during cytoreductive surgery with hyperthermic intraperitoneal chemotherapy
por: Ramirez, Maria F., et al.
Publicado: (2023) -
Assessment of Hyperthermic Intraperitoneal Chemotherapy to Eradicate Intraperitoneal Free Cancer Cells()
por: Ji, Zhonghe, et al.
Publicado: (2016) -
Anesthetic implications in hyperthermic intraperitoneal chemotherapy
por: Gupta, Nishkarsh, et al.
Publicado: (2019)